一文带你了解首个胆管癌靶向药培美替尼的功效和作用

This article will help you understand the efficacy and role of the first targeted drug for cholangiocarcinoma.

Pemetinib leads to constitutive activation of FGFR by activating FGFR amplification and fusion, thereby inhibiting FGFR1-3 phosphorylation and signaling and reducing cell viability. Pemetinib is a kinase inhibitor indicated for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) fusions or other rearrangements as detected by an FDA-approved test.

The approval of pemetinib was based on the results of a clinical trial involving 107 patients with locally advanced or metastatic cholangiocarcinoma. These patients have been previously treated and carry FGFR2 (fibroblast growth factor receptor 2) fusions or rearrangements.

The trial results showed that the overall response rate (ORR) of pemetinib reached 36%, of which 2.8% of patients had complete response and 33% of patients had partial response. Of the 38 patients who experienced a response, 24 patients (63%) had a response that lasted 6 months or longer, and 7 patients (18%) had a response that lasted 12 months or longer.

The most common adverse reactions in patients receiving pemetinib were: hyperphosphatemia and hypophosphatemia (electrolyte imbalance), alopecia (bald patches), diarrhea, indigestion, nausea, nail toxicity, fatigue, constipation, stomatitis (20% or more), pain or inflammation in the mouth, dry eyes, vomiting, joint pain, dry mouth, decreased appetite, abdominal pain, back pain, and dry skin.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: